CJC-1295 Without DAC: Advanced Growth Hormone Research Peptide

CJC-1295 Without DAC represents a significant advancement in peptide research as a modified version of the naturally occurring Growth Hormone Releasing Hormone (GHRH). This synthetic peptide consists of 30 amino acids and is specifically designed to stimulate the pituitary gland’s secretion of growth hormone. Unlike the CJC-1295 with DAC (Drug Affinity Complex), this version has a shorter half-life of approximately 30 minutes, which allows for more precise control in research settings.

Scientific Background and Mechanism of Action

The CJC-1295 Without DAC functions by binding to GHRH receptors on pituitary somatotrophs, stimulating the release of growth hormone. Research indicates that this peptide may increase growth hormone levels by 2-10 fold in test subjects. The absence of DAC in this formulation means it doesn’t bind to albumin, resulting in a shorter duration of action compared to its DAC counterpart.

According to studies published in PubMed, the modified structure of CJC-1295 Without DAC enhances its biological activity while maintaining a favorable safety profile in research settings. The peptide’s mechanism makes it particularly valuable for researchers studying growth hormone dynamics, metabolic processes, and tissue regeneration.

Research Applications

CJC-1295 Without DAC has garnered significant attention in the scientific community for its potential research applications:

• Growth Hormone Studies: Investigating the role of growth hormone in various physiological processes
• Metabolic Research: Examining effects on protein synthesis, fat metabolism, and glucose regulation
• Tissue Regeneration: Studying impacts on cellular repair and recovery mechanisms
• Anti-Aging Research: Exploring potential applications in age-related decline studies

The National Institutes of Health has recognized the importance of peptide research in advancing our understanding of endocrine function and metabolic processes.

Dosage and Administration in Research

For research purposes, CJC-1295 Without DAC is typically administered through subcutaneous injection. Due to its shorter half-life, researchers often employ multiple daily dosing schedules to maintain stable growth hormone levels. Typical research protocols range from 100-300 mcg per administration, with frequency determined by specific research objectives.

It’s important to note that all research should be conducted in accordance with institutional guidelines and ethical standards. Our CJC-1295 Without DAC is intended strictly for research purposes and not for human consumption.

Quality and Purity Standards

At Apeptide Biotech, we maintain stringent quality control measures for all our research peptides. Our CJC-1295 Without DAC undergoes comprehensive testing including:

• High-Performance Liquid Chromatography (HPLC) analysis
• Mass Spectrometry verification
• Microbiological testing
• Potency and stability assessments

Each batch of CJC-1295 Without DAC is accompanied by a certificate of analysis, ensuring researchers receive only the highest quality peptides for their studies.

Comparison with Other Growth Hormone Secretagogues

When compared to other growth hormone releasing peptides, CJC-1295 Without DAC offers distinct advantages for certain research applications:

• More precise control over growth hormone release due to shorter half-life
• Reduced risk of receptor desensitization with proper dosing protocols
• Compatibility with other research compounds for synergistic effect studies

Researchers can explore our complete selection of research peptides at Apeptide Biotech’s shop to find the most appropriate compounds for their specific studies.

Storage and Handling

Proper storage is essential to maintain the integrity of CJC-1295 Without DAC. We recommend storing the peptide at -20°C (or -4°F) in its lyophilized form. Once reconstituted, it should be refrigerated and used within the timeframe specified in the product documentation. Always follow aseptic techniques when handling research peptides to prevent contamination.

Research Considerations

While CJC-1295 Without DAC shows promise in various research applications, it’s important to approach studies with proper scientific methodology. Researchers should consider potential variables including:

• Subject-specific responses to growth hormone stimulation
• Interaction with other hormonal systems
• Long-term effects of repeated administration
• Dose-response relationships in different research models

For comprehensive information on growth hormone research, resources such as Wikipedia’s growth hormone-releasing hormone article and Google Scholar provide extensive scientific literature and study results.

Conclusion

CJC-1295 Without DAC represents a valuable tool in the researcher’s toolkit for studying growth hormone dynamics and related physiological processes. Its unique pharmacokinetic profile makes it particularly suitable for studies requiring precise control over growth hormone release. At Apeptide Biotech, we’re committed to providing researchers with the highest quality peptides to advance scientific understanding in this important field.

References

1. Teichman SL, et al. “Pharmacokinetic and pharmacodynamic characterization of a long-acting growth hormone-releasing hormone analog CJC-1295.” J Clin Endocrinol Metab. 2006.
2. US National Library of Medicine. “Growth hormone-releasing hormone.” PubMed Health.
3. NIH Office of Dietary Supplements. “Peptide Hormones Research Overview.”

Disclaimer: CJC-1295 Without DAC is intended for research purposes only and not for human consumption. All research should be conducted in compliance with applicable laws and institutional guidelines.